0001209191-19-054618.txt : 20191031 0001209191-19-054618.hdr.sgml : 20191031 20191031160413 ACCESSION NUMBER: 0001209191-19-054618 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191030 FILED AS OF DATE: 20191031 DATE AS OF CHANGE: 20191031 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Stein Steven H CENTRAL INDEX KEY: 0001673776 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-12400 FILM NUMBER: 191183658 MAIL ADDRESS: STREET 1: 1801 AUGUSTINE CUT-OFF CITY: WILMINGTON STATE: DE ZIP: 19803 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INCYTE CORP CENTRAL INDEX KEY: 0000879169 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 943136539 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1801 AUGUSTINE CUT-OFF CITY: WILMINGTON STATE: DE ZIP: 19803 BUSINESS PHONE: 3024986700 MAIL ADDRESS: STREET 1: 1801 AUGUSTINE CUT-OFF CITY: WILMINGTON STATE: DE ZIP: 19803 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE CORP DATE OF NAME CHANGE: 20030318 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE GENOMICS INC DATE OF NAME CHANGE: 20000710 FORMER COMPANY: FORMER CONFORMED NAME: INCYTE PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930902 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-10-30 0 0000879169 INCYTE CORP INCY 0001673776 Stein Steven H 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 0 1 0 0 EVP & Chief Medical Officer Common Stock 2019-10-30 4 A 0 50000 0.00 A 66473 D Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on October 30, 2019. The performance shares vest 100% on the third anniversary of the grant date of June 28, 2018, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date. Each performance share initially represented the right to receive one or more shares of common stock based on, and subject to, the achievement of certain clinical milestones determined by the Issuer's Compensation Committee in October 2019 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person was entitled to receive ranged from 0% to 100% of the number of performance shares awarded, and the performance criteria was achieved at the 100% level. This includes an aggregate of 63,951 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. /s/ Steven Stein 2019-10-31